DyAnsys

San Mateo, CAFounded 200111–50 employeesdyansys.comLinkedIn

Neuromodulation
Chronic pain

NeuroStimulation Medtech develops and manufactures medical devices for chronic pain management, opioid withdrawal support, post-operative pain, autonomic nervous system monitoring, and ECG assessment. Its portfolio combines auricular neurostimulation therapies with real-time heart rate variability and electrocardiographic monitoring technologies.

Visit dyansys.com ↗

Founded: 2001
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

Recent highlights

DyAnsys's most visible milestones remain regulatory and product-related rather than financing announcements. On Jul 18, 2022, the company's First Relief® wearable neurostimulator received FDA clearance for pain associated with diabetic nerve damage. On Jul 28, 2022, FDA clearance was announced for Primary Relief® to treat C-section pain, followed by coverage on Sep 27, 2022 describing the device's use for post-cardiac-surgery pain. These clearances extend DyAnsys's application of auricular neurostimulation across diabetic neuropathy and selected post-operative settings. The company also markets Drug Relief® for opioid-withdrawal symptom reduction and ANSiscope® for ECG and heart-rate-variability assessment. A Mar 25, 2025 market report referenced DyAnsys within the dysautonomia and autonomic-dysfunction market, indicating continued visibility in its core clinical domain. No publicly documented partnerships, awards, executive appointments, or financing events were available in the profile inputs. The company is listed as active and appears to operate at an estimated 11-50 employee scale, but current commercial adoption and revenue information are limited.

Market position

DyAnsys occupies a specialized position at the intersection of medical devices, neuromodulation, pain management, and autonomic-function diagnostics. Its differentiation is the combination of auricular percutaneous electrical nerve field stimulation with autonomic nervous system measurement, rather than a single-purpose pain device portfolio. First Relief®, Drug Relief®, and Primary Relief® address distinct use cases spanning diabetic neuropathic pain, opioid withdrawal, and post-operative pain, while ANSiscope® adds ECG and beat-to-beat heart-rate-variability analysis. Relative to general wearable pain technologies, DyAnsys emphasizes non-narcotic therapy, ear-based stimulation, treatment durations of up to 168 hours, and clinical applications tied to defined pain or withdrawal pathways. Its FDA clearances support credibility in the United States, while manufacturing and regulatory capabilities in India may support international expansion.

Growth & opportunities

DyAnsys's trajectory reflects a long operating history followed by a concentrated expansion of its neurostimulation portfolio. Founded in October 2001, the company initially built capabilities across ECG, autonomic nervous system assessment, and medical-device development. Its more recent inflection point was regulatory: First Relief® received FDA clearance on Jul 18, 2022 for diabetic neuropathic pain, and Primary Relief® received FDA clearance on Jul 28, 2022 for C-section pain. Coverage on Sep 27, 2022 connected Primary Relief® with post-cardiac-surgery pain, broadening the visible use case beyond the initial announcement. Drug Relief® extends the platform into opioid-withdrawal support, while ANSiscope® and ECScope 100™ provide diagnostic and cardiac-monitoring products that may support clinician engagement around autonomic function. The company is classified in the 11-50 employee range, with no reported hiring activity or layoffs and no disclosed funding history. As of Sep 30, 2026, the evidence supports product and regulatory progression but not a quantified growth rate.

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

What makes DyAnsys distinct

reccy insights

What makes DyAnsys distinct

01Combines autonomic nervous system measurement with non-narcotic auricular neurostimulation therapies.
02Offers FDA-cleared neurostimulation products for diabetic neuropathic pain, opioid-withdrawal symptom reduction, and selected post-surgical pain applications.
03Uses heart-rate-variability analysis for beat-to-beat autonomic monitoring.
04Supports wearable treatment delivery across chronic pain, post-operative pain, and opioid-withdrawal use cases.
05Maintains manufacturing and regulatory capabilities in India while targeting healthcare markets in the United States, Europe, Asia-Pacific, and the Middle East.

Technology & products5

Technology & products

Primary Relief®
A wearable neurostimulator that delivers continuous low-level electrical pulses to the ear for up to 72 hours to alleviate chronic pain symptoms through auricular neurostimulation therapy.
Drug Relief®
A percutaneous electrical nerve field stimulator worn behind the ear that provides auricular neurostimulation for up to 120 hours to reduce opioid-withdrawal symptoms during detoxification.
First Relief®
A percutaneous electrical nerve field stimulator that delivers auricular neurostimulation for up to 168 hours to treat diabetic neuropathic pain through electrical pulses via needles in the ear.
ANSiscope®
An ECG monitoring system that acquires, analyzes, displays, and records electrocardiographic data and measures heart-rate variability to assess autonomic nervous system function.
ECScope 100™
A multi-channel electrocardiograph that acquires, displays, and records 12-lead ECG signals from surface electrodes for clinical cardiac monitoring.

Show all 5 products

+ 2 more: ANSiscope®, ECScope 100™

Similar companies

Show all 6 companies

About DyAnsys

Products: Primary Relief®, Drug Relief®, First Relief®, ANSiscope®, ECScope 100™
Focus areas: Medical devices, neurostimulation, chronic pain, opioid withdrawal, autonomic nervous system, hrv, ecg monitoring, wearable healthcare
Headquarters: San Mateo, CA
Founded: 2001
Employees: 11–50
Patents granted: 4 (Crunchbase)
Trademarks: 6